Patent ID: 8012718

Claim:
A method of identifying markers in an individual correlated with the individual's likelihood developing increased body mass associated with the use of risperidone, comprising: assaying genetic material from the individual for the presence of at least one positive coefficient marker and at least one negative coefficient marker to produce a physiotype for the individual, wherein the positive coefficient marker is rs6837793 corresponding to SEQ ID NO. 243 and the negative coefficient marker is rs8179183 corresponding to SEQ ID NO. 131, wherein at least one positive coefficient marker and at least one negative coefficient marker are oppositely associated with the likelihood of developing increased body mass associated with the use of risperidone in the individual, and wherein the presence of a variant allele at position 22 of SEQ ID NO: 243 is associated with a likelihood of an increase in body mass associated with the use of risperidone in the human individual and the presence of a variant allele at position 22 of SEQ ID NO: 131 is associated with a likelihood of a decrease in body mass associated with the use of risperidone in the human individual.